Paradigm Biopharmaceuticals (PBIGF, $0.13) was a top loser over the last three months, falling -2 to $0.13 per share. A.I.dvisor analyzed 857 stocks in the Biotechnology Industry for the 3-month period ending September 30, 2024, and found that of them (4) exhibited an Uptrend while of them (5) demonstrated a Downtrend.